Javascript must be enabled to continue!
2884. Incidence of Invasive Fungal Infections After Pancreas Transplantation
View through CrossRef
Abstract
Background
There is scarce data surrounding the epidemiology of invasive fungal infections (IFI) after pancreas transplantation (PT). Our centers’ PT protocols recommend universal fluconazole prophylaxis for at least 1 month, which is extended to 1 year for recipients who live in Coccidioides endemic areas. The purpose of our study was to evaluate the epidemiology of IFIs after PT while on our antifungal prophylaxis protocol.
Methods
A retrospective cohort study was performed among adult patients who underwent PT at Mayo Clinic sites in Arizona, Florida, or Minnesota between January 1, 2010 and December 31, 2020. IFI was defined based on EORTC/MSGERC criteria. The primary aim was to describe epidemiology and timing of IFI after PT, particularly in the context of the universal antifungal prophylaxis protocol.
Results
Among 482 pancreas transplant recipients, 35 developed IFIs (7.3%). All patients received antifungal prophylaxis per protocol for a median duration of 33 days (Figure 1). Median duration from time of transplant to IFI was 16 (IQR 10.5-28.2) days for Candida IFIs versus 529 (IQR 192.5-1195.0) days for non-Candida IFI. 20 IFIs (57.1%) were secondary to Candida species with 45% of these cases caused by either C. glabrata or C. krusei (Figure 2). 90% were on antifungal prophylaxis (85% fluconazole) at time of diagnosis of invasive candidiasis. All the Candida IFIs were intra-abdominal infections. Amongst the 15 non-Candida IFIs (42.9%), 9 were secondary to endemic mycoses and 4 were secondary to invasive molds.
Conclusion
Our study shows a high incidence of IFIs secondary to Candida, with few patients diagnosed with non-Candida IFIs (Figure 3). Non-Candida IFIs, mostly secondary to endemic mycoses, occurred more than a year after transplant. Patients are at highest risk for Candida IFIs within the first 30 days after PT, likely secondary to organ space surgical site infections, despite receipt of antifungal prophylaxis. Breakthrough invasive candidiasis occurred in 90% of cases. Though our study lacked a comparator group without prophylaxis, these data question the effectiveness of fluconazole prophylaxis after PT.
Disclosures
All Authors: No reported disclosures
Oxford University Press (OUP)
Title: 2884. Incidence of Invasive Fungal Infections After Pancreas Transplantation
Description:
Abstract
Background
There is scarce data surrounding the epidemiology of invasive fungal infections (IFI) after pancreas transplantation (PT).
Our centers’ PT protocols recommend universal fluconazole prophylaxis for at least 1 month, which is extended to 1 year for recipients who live in Coccidioides endemic areas.
The purpose of our study was to evaluate the epidemiology of IFIs after PT while on our antifungal prophylaxis protocol.
Methods
A retrospective cohort study was performed among adult patients who underwent PT at Mayo Clinic sites in Arizona, Florida, or Minnesota between January 1, 2010 and December 31, 2020.
IFI was defined based on EORTC/MSGERC criteria.
The primary aim was to describe epidemiology and timing of IFI after PT, particularly in the context of the universal antifungal prophylaxis protocol.
Results
Among 482 pancreas transplant recipients, 35 developed IFIs (7.
3%).
All patients received antifungal prophylaxis per protocol for a median duration of 33 days (Figure 1).
Median duration from time of transplant to IFI was 16 (IQR 10.
5-28.
2) days for Candida IFIs versus 529 (IQR 192.
5-1195.
0) days for non-Candida IFI.
20 IFIs (57.
1%) were secondary to Candida species with 45% of these cases caused by either C.
glabrata or C.
krusei (Figure 2).
90% were on antifungal prophylaxis (85% fluconazole) at time of diagnosis of invasive candidiasis.
All the Candida IFIs were intra-abdominal infections.
Amongst the 15 non-Candida IFIs (42.
9%), 9 were secondary to endemic mycoses and 4 were secondary to invasive molds.
Conclusion
Our study shows a high incidence of IFIs secondary to Candida, with few patients diagnosed with non-Candida IFIs (Figure 3).
Non-Candida IFIs, mostly secondary to endemic mycoses, occurred more than a year after transplant.
Patients are at highest risk for Candida IFIs within the first 30 days after PT, likely secondary to organ space surgical site infections, despite receipt of antifungal prophylaxis.
Breakthrough invasive candidiasis occurred in 90% of cases.
Though our study lacked a comparator group without prophylaxis, these data question the effectiveness of fluconazole prophylaxis after PT.
Disclosures
All Authors: No reported disclosures.
Related Results
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Fungal Infections in Chronic Lymphocytic Leukemia before and after Treatment
Background : Patients with Chronic Lymphocytic Leukemia (CLL) are susceptible to infections due to impaired immunity, from both complications of disease and treatments. Specific tr...
UNDERSTANDING THE EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS AND DIAGNOSTIC APPROACHES OF FUNGAL INFECTIONS
UNDERSTANDING THE EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS AND DIAGNOSTIC APPROACHES OF FUNGAL INFECTIONS
Fungal infections represent a significant worldwide (universal) health concern, affecting diverse populations with varying degrees of severity. This review delves into the epidemio...
PS1154 INFECTIONS IN CLL PATIENTS RECEIVING IBRUTINIB: INCIDENCE AND PREDISPOSING FACTORS
PS1154 INFECTIONS IN CLL PATIENTS RECEIVING IBRUTINIB: INCIDENCE AND PREDISPOSING FACTORS
Background:Infections are a typical complication of chronic lymphocytic leukemia (CLL). Guidelines for prevention of infections in patients with CLL receiving ibrutinib is lacking,...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract
Introduction
Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Allergic Fungal Rhinosinusitis: A Case Study
Allergic Fungal Rhinosinusitis: A Case Study
Fungal sinusitis is generalized as invasive and non-invasive types. The invasive type has fungal hyphae in the mucosa, submucosa, bones, or in vascular channels of the paranasal si...
VARIABILITY OF PAIN SYNDROME AND ULTRASONOGRAPHIC SIGNS OF PANCREATIC FIBROSIS IN PATIENTS WITH CHRONIC PANCREATITIS COMORBID WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
VARIABILITY OF PAIN SYNDROME AND ULTRASONOGRAPHIC SIGNS OF PANCREATIC FIBROSIS IN PATIENTS WITH CHRONIC PANCREATITIS COMORBID WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
The purpose of the study – to determine the intensity of pain and pancreatic fi brosisin patients with chronic pancreatitis (CP) with comorbidity in chronic obstructivepulmonary di...
The Incidence of Fungal Infections in Patients Treated with Tocilizumab for Severe COVID-19 Pneumonia Requiring High Care or ICU Admission: A Retrospective Cohort Study
The Incidence of Fungal Infections in Patients Treated with Tocilizumab for Severe COVID-19 Pneumonia Requiring High Care or ICU Admission: A Retrospective Cohort Study
Background: Critically ill COVID-19 patients often experience immune dysregulation, leading to cytokine release syndrome and an increased susceptibility to nosocomial infections, i...

